Session

IBD (Posters)

PREDICTION OF INFLAMMATORY BOWEL DISEASE COURSE BASED ON FAECAL VOLATILE ORGANIC COMPOUNDS
PREDICTION OF INFLAMMATORY BOWEL DISEASE COURSE BASED ON FAECAL VOLATILE ORGANIC COMPOUNDS

QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS
QUALITY OF LIFE OUTCOMES FROM PURSUIT-M TRIAL FURTHER SUPPORT EARLY DOSE OPTIMIZATION OF GOLIMUMAB IN MODERATE-TO-SEVERE ACTIVE ULCERATIVE COLITIS

THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS
THE JAK-3 AND TYK-2 / STAT PATHWAYS ARE ACTIVATED IN MODERATE TO SEVERE ULCERATIVE COLITIS

INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE
INFLUENCE OF THE INTERVAL OF TIME BETWEEN ANTI-TNF AND VEDOLIZUMAB OR USTEKINUMAB IN THE RESPONSE TO TREATMENT IN PATIENTS WITH INFLAMMATORY BOWEL DISEASE

TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY
TOFACITINIB IN ULCERATIVE COLITIS: REAL WORLD EVIDENCE FROM ENEIDA REGISTRY

PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC
PATIENT REPORTED OUTCOME SEVERITY DOES NOT IMPACT ENDOSCOPIC HEALING IN CROHN'S DISEASE: A POST-HOC ANALYSIS OF SONIC

INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE
INTRODUCTION OF BOWEL ULTRASONOGRAPHY FOR FOLLOW-UP OF PEDIATRIC INFLAMMATORY BOWEL DISEASE: A SINGLE-CENTER EXPERIENCE

CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY
CLINICAL EFFICACY, DRUG SUSTAINABILITY AND RESULTS FROM THERAPEUTIC DRUG MONITORING IN CROHN'S DISEASE PATIENTS TREATED WITH USTEKINUMAB - 1-YEAR FOLLOW-UP OF A PROSPECTIVE, NATIONWIDE, MULTICENTER COHORT FROM HUNGARY

MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)
MANAGEMENT AND UNMET NEED AMONGST MILD AND MODERATE/ SEVERE CD AND UC PATIENTS: FINDINGS FROM A CROSS SECTIONAL STUDY IN THE US AND FRANCE, GERMANY, ITALY, SPAIN, UK (EU5)

INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY
INTESTINAL ULTRASOUND IN ULCERATIVE COLITIS PATIENTS TREATED WITH TOFACITINIB PREDICTS ENDOSCOPIC OUTCOMES, A LONGITUDINAL PROSPECTIVE COHORT STUDY

A MACHINE LEARNING APPROACH IDENTIFIES SPECIFIC MICROBIOTA SIGNATURE ASSOCIATED TO VARIOUS DEGREE OF ULCERATIVE COLITIS
A MACHINE LEARNING APPROACH IDENTIFIES SPECIFIC MICROBIOTA SIGNATURE ASSOCIATED TO VARIOUS DEGREE OF ULCERATIVE COLITIS

VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE
VEDOLIZUMAB IV VERSUS ADALIMUMAB TO TREAT MODERATELY-TO-SEVERELY ACTIVE ULCERATIVE COLITIS: COST-EFFECTIVENESS FROM A US PRIVATE PAYER PERSPECTIVE

INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE
INTEGRATION OF EHEALTH FOR PAEDIATRIC IBD IN REAL LIFE IS SAFE

THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS
THE VARIABILITY IN THE DISTRIBUTION OF HISTOLOGICAL ACTIVITY IN COLONIC SEGMENTS IN PATIENTS WITH ULCERATIVE COLITIS AND THE IMPACT HEREOF ON THE DEVELOPMENT OF AI TOOLS

MESALAZINE INDUCES EARLY HISTO-ENDOSCOPIC MUCOSAL HEALING IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS
MESALAZINE INDUCES EARLY HISTO-ENDOSCOPIC MUCOSAL HEALING IN ACTIVE MILD-MODERATE ULCERATIVE COLITIS: POST-HOC ANALYSIS OF POOLED DATA FROM 4 DOUBLE-BLIND, DOUBLE-DUMMY, MULTICENTER, RANDOMIZED TRIALS

COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS
COMPARATIVE BIOAVAILABILITY OF NOVEL CYCLOSPORINE FORMULATIONS VERSUS REFERENCE ORAL CYCLOSPORINE IN HEALTHY SUBJECTS UNDER FASTING CONDITIONS

RESPONSE TO INDUCTION TREATMENT WITH BIOLOGICALS IN A MULTICENTER, PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS - PRELIMINARY RESULTS FROM THE DANISH IBD BIOBANK PROJECT
RESPONSE TO INDUCTION TREATMENT WITH BIOLOGICALS IN A MULTICENTER, PROSPECTIVE COHORT OF BIOLOGICAL-NAÏVE IBD PATIENTS - PRELIMINARY RESULTS FROM THE DANISH IBD BIOBANK PROJECT

TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT
TREATMENT OF ADULTS WITH THE CLOSTRIDIA STRAIN LIVE BIOTHERAPEUTIC PRODUCT VE202 RESULTS IN SUSTAINED AND DURABLE COLONIZATION OF THE HEALTHY HUMAN GUT

METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS
METHOD COMPARISON STUDY OF TWO COMMERCIALLY AVAILABLE TDM TEST FOR THE MEASUREMENT OF USTEKINUMAB LEVELS

TRANSCRIPTIONAL CHANGES AFTER BUDESONIDE TREATMENT IN COLLAGENOUS COLITIS PATIENTS
TRANSCRIPTIONAL CHANGES AFTER BUDESONIDE TREATMENT IN COLLAGENOUS COLITIS PATIENTS

Item 41 - 60 / 558
1 2
3
4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28